Riluzole improves outcome following ischemia-reperfusion injury to the spinal cord by preventing delayed paraplegia

Neuroscience

Volumn 265, Issue , 2014, Pages 302-312

  Wu, Y ^a,c   Satkunendrarajah, K ^a   Fehlings, M G ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Drug treatment; Ischemia; Ischemia reperfusion injury; Riluzole; Spinal cord injury

Indexed keywords

CHOLINE ACETYLTRANSFERASE; GLIAL FIBRILLARY ACIDIC PROTEIN; RILUZOLE; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTOSIS; CELL INFILTRATION; CELL NUCLEUS; CONTROLLED STUDY; FEMALE; GRAY MATTER; MACROPHAGE; MICROGLIA; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PARAPLEGIA; PRIORITY JOURNAL; RAT; SPINAL CORD DORSAL HORN; SPINAL CORD INJURY; SPINAL CORD VENTRAL HORN; ANIMAL; COMPLICATION; PATHOLOGY; REPERFUSION INJURY; SPINAL CORD INJURIES; TREATMENT OUTCOME;

ANIMALS; FEMALE; NEUROPROTECTIVE AGENTS; PARAPLEGIA; RATS; REPERFUSION INJURY; RILUZOLE; SPINAL CORD INJURIES; TREATMENT OUTCOME;

EID: 84894657597     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.01.059     Document Type: Article

References (70)

1. Agrawal S.K., Fehlings M.G. Mechanisms of secondary injury to spinal cord axons in vitro: role of Na+, Na(+)-K(+)-ATPase, the Na(+)-H+ exchanger, and the Na(+)-Ca2+ exchanger. J Neurosci 1996, 16:545-552.
2. Agrawal S.K., Fehlings M.G. The effect of the sodium channel blocker QX-314 on recovery after acute spinal cord injury. J Neurotrauma 1997, 14:81-88.
3. Almasanu B.P., Owensby J.R., Pavlakis S.G., Edwards J.H. Spinal cord infarction in meningitis: polygenic risk factors. Pediatr Neurol 2005, 32:124-126.
4. Azbill R.D., Mu X., Springer J.E. Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. Brain Res 2000, 871:175-180.
5. Baptiste D.C., Fehlings M.G. Pharmacological approaches to repair the injured spinal cord. J Neurotrauma 2006, 23:318-334.
6. Basso D.M., Beattie M.S., Bresnahan J.C. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 1995, 12:1-21.
7. Beghi E., Chio A., Couratier P., Esteban J., Hardiman O., Logroscino G., Millul A., Mitchell D., Preux P.M., Pupillo E., Stevic Z., Swingler R., Traynor B.J., Van Den Berg L.H., Veldink J.H. Zoccolella S (2011) The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler 2011, 12(1):1-10. 10.3109/17482968.2010.502940.
8. Cambria R.P., Davison J.K., Zannetti S., L'Italien G., Atamian S. Thoracoabdominal aneurysm repair: perspectives over a decade with the clamp-and-sew technique. Ann Surg 1997, 226:294-303. discussion 303-295.
9. Cambria R.P., Davison J.K., Zannetti S., L'Italien G., Brewster D.C., Gertler J.P., Moncure A.C., LaMuraglia G.M., Abbott W.M. Clinical experience with epidural cooling for spinal cord protection during thoracic and thoracoabdominal aneurysm repair. J Vasc Surg 1997, 25:234-241. discussion 241-233.
10. Cheng M.Y., Lyu R.K., Chang Y.J., Chen C.M., Chen S.T., Wai Y.Y., Ro L.S. Concomitant spinal cord and vertebral body infarction is highly associated with aortic pathology: a clinical and magnetic resonance imaging study. J Neurol 2009, 256:1418-1426.
11. Chow D.S., Teng Y., Toups E.G., Aarabi B., Harrop J.S., Shaffrey C.I., Johnson M.M., Boakye M., Frankowski R.F., Fehlings M.G., Grossman R.G. Pharmacology of riluzole in acute spinal cord injury. J Neurosurg Spine 2012, 17:129-140.
12. Dessi F., Ben-Ari Y., Charriaut-Marlangue C. Riluzole prevents anoxic injury in cultured cerebellar granule neurons. Eur J Pharmacol 1993, 250:325-328.
13. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996, 47:S233-241.
14. Dublin A.B., Latchaw R.E., Herrera D.A., Dahlin B.C. Delayed complication after embolotherapy of a vertebral arteriovenous fistula: spinal cord ischemia. J Vasc Interv Radiol 2010, 21:392-393.
15. Dumont R.J., Okonkwo D.O., Verma S., Hurlbert R.J., Boulos P.T., Ellegala D.B., Dumont A.S. Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin Neuropharmacol 2001, 24:254-264.
16. Estrera A.L., Miller C.C., Huynh T.T., Azizzadeh A., Porat E.E., Vinnerkvist A., Ignacio C., Sheinbaum R., Safi H.J. Preoperative and operative predictors of delayed neurologic deficit following repair of thoracoabdominal aortic aneurysm. J Thorac Cardiovasc Surg 2003, 126:1288-1294.
17. Etz C.D., Luehr M., Kari F.A., Bodian C.A., Smego D., Plestis K.A., Griepp R.B. Paraplegia after extensive thoracic and thoracoabdominal aortic aneurysm repair: does critical spinal cord ischemia occur postoperatively?. J Thorac Cardiovasc Surg 2008, 135:324-330.
18. Fehlings M.G., Agrawal S. Role of sodium in the pathophysiology of secondary spinal cord injury. Spine 1995, 20:2187-2191.
19. Fehlings M.G., Tator C. A review of spinal cord regeneration. Adv Trauma 1988, 3:223-240.
20. Frizzo M.E., Dall'Onder L.P., Dalcin K.B., Souza D.O. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol 2004, 24:123-128.
21. Giuliani A., Mettimano M., Viviani D., Scagliusi A., Bruno A., Russo A., Rotoli M., Savi L. An uncommon case of systemic mucormycosis associated with spinal cord infarction in a recently diagnosed diabetic. Int J Immunopathol Pharmacol 2010, 23:355-358.
22. Guzman-Lenis M.S., Navarro X., Casas C. Drug screening of neuroprotective agents on an organotypic-based model of spinal cord excitotoxic damage. Restor Neurol Neurosci 2009, 27:335-349.
23. Hains B.C., Waxman S.G. Sodium channel expression and the molecular pathophysiology of pain after SCI. Prog Brain Res 2007, 161:195-203.
24. Hobai I.A., Bittner E.A., Grecu L. Perioperative spinal cord infarction in nonaortic surgery: report of three cases and review of the literature. J Clin Anesth 2008, 20:307-312.
25. Holtzman D.A., Pfaff D.W., Schwartz-Giblin S. Axial muscle EMG responses evoked by cutaneous flank nerves in the female rat: effects of spinal transection, steroid hormones, and anesthesia. Brain Res 1992, 595:39-49.
26. Johnson L.S., Goetcheus A., Corso P.J., O'Donnell S.D. Late-onset spinal cord ischemia after an elephant trunk procedure with subsequent thoracic endovascular aneurysm repair. J Vasc Surg 2010, [Epub ahead of print] PubMed PMID: 20620000.
27. Kolesar D., Kolesarova M., Pavel J., Davidova A., Marsala J., Lukacova N. Region-specific sensitivity of the spinal cord to ischemia/reperfusion: the dynamic of changes in catalytic NOS activity. J Physiol Sci 2009, 59:97-103.
28. Kucharova K., Lukacova N., Pavel J., Radonak J., Hefferan M.P., Kolesar D., Kolesarova M., Marsala M., Marsala J. Spatiotemporal alterations of the NO/NOS neuronal pools following transient abdominal aorta occlusion: morphological and biochemical studies in the rabbit. Cell Mol Neurobiol 2006, 26:1295-1310.
29. Lamanauskas N., Nistri A. Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur J Neurosci 2008, 27:2501-2514.
30. Lang-Lazdunski L., Heurteaux C., Dupont H., Widmann C., Lazdunski M. Prevention of ischemic spinal cord injury: comparative effects of magnesium sulfate and riluzole. J Vasc Surg 2000, 32:179-189.
31. Lang-Lazdunski L., Heurteaux C., Mignon A., Mantz J., Widmann C., Desmonts J., Lazdunski M. Ischemic spinal cord injury induced by aortic cross-clamping: prevention by riluzole. Eur J Cardiothorac Surg 2000, 18:174-181.
32. Lang-Lazdunski L., Heurteaux C., Vaillant N., Widmann C., Lazdunski M. Riluzole prevents ischemic spinal cord injury caused by aortic crossclamping. J Thorac Cardiovasc Surg 1999, 117:881-889.
33. Le Liboux A., Cachia J.P., Kirkesseli S., Gautier J.Y., Guimart C., Montay G., Peeters P.A., Groen E., Jonkman J.H., Wemer J. A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers. J Clin Pharmacol 1999, 39:480-486.
34. Le Liboux A., Lefebvre P., Le Roux Y., Truffinet P., Aubeneau M., Kirkesseli S., Montay G. Single- and multiple-dose pharmacokinetics of riluzole in white subjects. J Clin Pharmacol 1997, 37:820-827.
35. Ludwig M.A., Burns S.P. Spinal cord infarction following cervical transforaminal epidural injection: a case report. Spine (Phila Pa 1976) 2005, 30:E266-E268.
36. Mackey M.E., Wu Y., Hu R., DeMaro J.A., Jacquin M.F., Kanellopoulos G.K., Hsu C.Y., Kouchoukos N.T. Cell death suggestive of apoptosis after spinal cord ischemia in rabbits. Stroke 1997, 28:2012-2017.
37. MacMahon P.J., Crosbie I., Kavanagh E.C. Reducing the risk of spinal cord infarction during transforaminal steroid injections. Am J Neuroradiol 2010, 31:E32.
38. Manara R., Calderone M., Severino M.S., Citton V., Toldo I., Laverda A.M., Sartori S. Spinal cord infarction due to fibrocartilaginous embolization: the role of diffusion weighted imaging and short-tau inversion recovery sequences. J Child Neurol 2010, 25:1024-1028.
39. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., Lasser N.L., Trevisan M., Black H.R., Heckbert S.R., Detrano R., Strickland O.L., Wong N.D., Crouse J.R., Stein E., Cushman M., Alving B., Rossouw J.E., Pottern L., Ludlam S., McGowan J.A., Prentice R., Anderson G., LaCroix A., Patterson R., McTiernan A., Cochrane B., Hunt J., Tinker L., Kooperberg C., McIntosh M., Wang C.Y., Chen C., Bowen D., Kristal A., Stanford J., Urban N., Weiss N., White E., Shumaker S., Rautaharju P., Prineas R., Naughton M., Stein E., Laskarzewski P., Cummings S., Nevitt M., Dockrell M., Harnack L., Cammarata F., Lindenfelser S., Psaty B., Heckbert S., Wassertheil-Smoller S., Frishman W., Wylie-Rosett J., Barad D., Freeman R., Hays J., Young R., Anderson J., Lithgow S., Bray P., Manson J., Buring J., Gaziano J.M., Rexrode K., Chae C., Assaf A.R., Carleton R., Wheeler C., Eaton C., Cyr M., Phillips L., Pedersen M., Strickland O., Huber M., Porter V., Beresford S.A.A., Taylor V.M., Woods N.F., Henderson M., Kestin M., Hsia J., Gaba N., Ascensao J., Laowattana S., Chlebowski R., Detrano R., Nelson A., Heiner J., Marshall J., Ritenbaugh C., Valanis B., Elmer P., Stevens V., Karanja N., Caan B., Sidney S., Bailey G., Hirata J., Kotchen J.M., Barnabei V., Kotchen T.A., Gilligan M.A.C., Neuner J., Howard B.V., Adams-Campbell L., Passaro M., Rainford M., Agurs-Collins T., Van Horn L., Greenland P., Khandekar J., Liu K., Rosenberg C., Black H., Powell L., Mason E., Stefanick M.L., Hlatky M.A., Chen B., Stafford R.S., Giudice L.C., Lane D., Granek I., Lawson W., San Roman G., Messina C., Jackson R., Harris R., Frid D., Mysiw W.J., Blumenfeld M., Lewis C.E., Oberman A., Fouad M.N., Shikany J.M., West D.S., Bassford T., Mattox J., Ko M., Lohman T., Trevisan M., Wactawski-Wende J., Graham S., Chang J., Smit E., Robbins J., Yasmeen S., Lindfors K., Stern J., Hubbell A., Frank G., Wong N., Greep N., MoOnk B., Judd H., Heber D., Elashoff R., Langer R.D., Criqui M.H., Talavera G.T., Garland C.F., Hanson R.E., Gass M., Wernke S., Watts N., Limacher M., Perri M., Kaunitz A., Williams R.S., Brinson Y., Curb D., Petrovitch H., Rodriguez B., Masaki K., Sharma S., Wallace R., Torner J., Johnson S., Snetselaar L., VanVoorhis B., Ockene I., Yood R., Aronson P., Lasser N., Hymowitz N., Lasser V., Safford M., Kostis J., O'Sullivan M.J., Parker L., Estape R., Fernandez D., Margolis K.L., Grimm R.H., Hunninghake D.B., LaValleur J., Hall K.M., Brunner R., St Jeor S., Graettinger W., Oujevolk V., Heiss G., Haines P., Ontjes D., Sueta C., Wells E., Kuller L., Caggiula A., Cauley J., Berga S., Milas N.C., Johnson K.C., Satterfield S., Ke T.W., Vile J., Tylavsky F., Brzyski R., Schenken R., Trabal J., Rodriguez-Sifuentes M., Mouton C., Allen C., Laube D., McBride P., Mares-Perlman J., Loevinger B., Burke G., Crouse R., Parsons L., Vitolins M., Hendrix S., Simon M., McNeeley G., Gordon P., Makela P., WsHI Investigat. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine 2003, 349:523-534.
40. Masson C., Bardin T. Desproges-Gotteron artery, spinal cord infarction, and transforaminal glucocorticoid injections. Joint Bone Spine 2009, 76:120-121. author reply 121-122.
41. Matsumoto S., Matsumoto M., Yamashita A., Ohtake K., Ishida K., Morimoto Y., Sakabe T. The temporal profile of the reaction of microglia, astrocytes, and macrophages in the delayed onset paraplegia after transient spinal cord ischemia in rabbits. Anesth Analg 2003, 96:1777-1784. table of contents.
42. McTigue D.M., Tripathi R., Wei P., Lash A.T. The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Exp Neurol 2007, 205:396-406.
43. Miller R.G., Mitchell J.D., Lyon M., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007, CD001447.
44. Millichap J.J., Sy B.T., Leacock R.O. Spinal cord infarction with multiple etiologic factors. J Gen Intern Med 2007, 22:151-154.
45. Mu X., Azbill R.D., Springer J.E. Riluzole improves measures of oxidative stress following traumatic spinal cord injury. Brain Res 2000, 870:66-72.
46. Ng M.T., Stammers A.T., Kwon B.K. Vascular Disruption and the Role of Angiogenic Proteins After Spinal Cord Injury. Transl Stroke Res 2011, 2:474-491.
47. Nogradi A., Szabo A., Pinter S., Vrbova G. Delayed riluzole treatment is able to rescue injured rat spinal motoneurons. Neuroscience 2007, 144:431-438.
48. Pratt J., Rataud J., Bardot F., Roux M., Blanchard J.C., Laduron P.M., Stutzmann J.M. Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia. Neurosci Lett 1992, 140:225-230.
49. Rivlin A.S., Tator C.H. Regional spinal cord blood flow in rats after severe cord trauma. J Neurosurg 1978, 49:844-853.
50. Robles L.A. Traumatic spinal cord infarction in a child: case report and review of literature. Surg Neurol 2007, 67:529-534.
51. Rosenthal D. Spinal cord ischemia after abdominal aortic operation: is it preventable?. J Vasc Surg 1999, 30:391-397.
52. Safi H.J., Subramaniam M.H., Miller C.C., Coogan S.M., Iliopoulos D.C., Winnerkvist A., Le Blevec D., Bahnini A. Progress in the management of type I thoracoabdominal and descending thoracic aortic aneurysms. Ann Vasc Surg 1999, 13:457-462.
53. Schwartz G., Fehlings M.G. Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. J Neurosurg 2001, 94:245-256.
54. Schwartz G., Fehlings M.G. Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res 2002, 137:177-190.
55. Schwartz G, Fehlings MG (2002b) Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. In: Progress in Brain Research, vol. 137 (McKerracher, L. et al., eds), pp 177-190: Elsevier Science B.V.
56. Stutzmann J.M., Pratt J., Boraud T., Gross C. The effect of riluzole on post-traumatic spinal cord injury in the rat. Neuroreport 1996, 7:387-392.
57. Sueda T., Okada K., Orihashi K., Sugawara Y., Kouchi K., Imai K. Cold blood spinal cord plegia for prediction of spinal cord ischemia during thoracoabdominal aneurysm repair. Ann Thorac Surg 2002, 73:1155-1159.
58. Swerdlow N.R., Martinez Z.A., Hanlon F.M., Platten A., Farid M., Auerbach P., Braff D.L., Geyer M.A. Toward understanding the biology of a complex phenotype: rat strain and substrain differences in the sensorimotor gating-disruptive effects of dopamine agonists. J Neurosci 2000, 20:4325-4336.
59. Taira Y., Marsala M. Effect of proximal arterial perfusion pressure on function, spinal cord blood flow, and histopathologic changes after increasing intervals of aortic occlusion in the rat. Stroke 1996, 27:1850-1858.
60. Takaba H., Fukuda K., Yao H. Substrain differences, gender, and age of spontaneously hypertensive rats critically determine infarct size produced by distal middle cerebral artery occlusion. Cell Mol Neurobiol 2004, 24:589-598.
61. Tator C.H., Fehlings M.G. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 1991, 75:15-26.
62. Thone J., Hohaus A., Bickel A., Erbguth F. Severe spinal cord ischemia subsequent to fibrocartilaginous embolism. J Neurol Sci 2007, 263:211-213.
63. Turkoz A., Gulcan O., Kizilkilic O., Kocum A., Turkoz R. Spinal cord ischemia caused by cardiac arrest secondary to pericardial effusion. J Cardiothorac Vasc Anesth 2007, 21:91-92.
64. Ueno T., Furukawa K., Katayama Y., Itoh T. Protection against ischemic spinal cord injury: one-shot perfusion cooling and percutaneous topical cooling. J Vasc Surg 1994, 19:882-887.
65. Uppal S., Dash S., Sharer L., Clark Lambert W., Heller D.S., Pullicino P. Spinal cord infarction secondary to nucleus pulposus embolization in pregnancy. Mod Pathol 2004, 17:121-124.
66. Wahl F., Allix M., Plotkine M., Boulu R.G. Effect of riluzole on focal cerebral ischemia in rats. Eur J Pharmacol 1993, 230:209-214.
67. Weber P., Vogel T., Bitterling H., Utzschneider S., von Schulze Pellengahr C., Birkenmaier C. Spinal cord infarction after operative stabilisation of the thoracic spine in a patient with tuberculous spondylodiscitis and sickle cell trait. Spine (Phila Pa 1976) 2009, 34:E294-E297.
68. Wokke J. Riluzole. Lancet 1996, 348:795-799.
69. Wu Y., Satkunendrarajah K., Teng Y., Chow D.S., Buttigieg J., Fehlings M.G. Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury. J Neurotrauma 2013, 30:441-452.
70. Yoon Y.W., Lee D.H., Lee B.H., Chung K., Chung J.M. Different strains and substrains of rats show different levels of neuropathic pain behaviors. Exp Brain Res 1999, 129:167-171.